Statement: Cohort 2 of the primary trial recorded three times as many cases of Leukopenia as cohort 1.
Primary_evidence: Adverse Events 1:   Total: 27/94 (28.72%)   Anaemia 2/94 (2.13%)   Febrile neutropenia 2/94 (2.13%)   Leukopenia 1/94 (1.06%)   Neutropenia 0/94 (0.00%)   Thrombocytopenia 1/94 (1.06%)   Arrhythmia 0/94 (0.00%)   Atrial fibrillation 0/94 (0.00%)   Cardiac failure congestive 0/94 (0.00%)   Cardiomyopathy 0/94 (0.00%)   Pericardial effusion 0/94 (0.00%)   Tachycardia 0/94 (0.00%) Adverse Events 2:   Total: 36/93 (38.71%)   Anaemia 2/93 (2.15%)   Febrile neutropenia 9/93 (9.68%)   Leukopenia 3/93 (3.23%)   Neutropenia 4/93 (4.30%)   Thrombocytopenia 1/93 (1.08%)   Arrhythmia 1/93 (1.08%)   Atrial fibrillation 1/93 (1.08%)   Cardiac failure congestive 3/93 (3.23%)   Cardiomyopathy 2/93 (2.15%)   Pericardial effusion 1/93 (1.08%)   Tachycardia 1/93 (1.08%)